Skip to NavigationSkip to content

spinal muscular dystrophy

NICE rejects Biogen's spinal muscular dystrophy drug Spinraza after long delay

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available treatment for the condition.

The news is the latest in a series of roadblocks for the drug. Following its approval last year, review of Spinraza was delayed by the institute until January this year because of contention over how to how to handle its route to market. This time round, NICE took issue with the drug’s price tag.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches